Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Tim Behrens is among the laureates and finalists of the 2018 Blavatnik Awards for Young Scientists in the United Kingdom, announced today by the Blavatnik Family Foundation and the New York Academy of Sciences.

Image courtesy of Nick Irving

One laureate in each of the three Blavatnik Awards categories—Life Sciences, Physical Sciences & Engineering, and Chemistry—will each receive a prize of US$100,000, and two finalists in each category will each receive US$30,000. The Blavatnik Awards in the UK are the largest unrestricted cash prizes available exclusively to young scientists in the UK.

Professor Timothy Behrens of the Nuffield Department of Clinical Neurosciences has been named as a Life Sciences Finalist. Professor Behrens investigates the biology of the brain that underlies human behaviour. By combining mathematical models with behavioural experiments and neural recordings, he has uncovered at a cellular level how the brain stores abstract information about relationships between things in the world, and how we use this mental map in decision-making. His discoveries have applications in neural network computing and artificial intelligence, but also on our understanding of cognition and mental health.

Read more on the University website

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.